Related Experiment Video

Updated: Aug 4, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

504

Clinical implications of lncRNA LINC-PINT in cancer

Ihtisham Bukhari1, Muhammad Riaz Khan2, Fazhan Li1

  • 1Henan Key Laboratory of Helicobacter pylori, Microbiota and Gastrointestinal Cancer, Marshall Medical Research Center, Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Frontiers in Molecular Biosciences
|April 3, 2023
PubMed

Insights

Long noncoding RNAs (lncRNAs) show therapeutic promise, especially LINC-PINT, a potential cancer biomarker. LINC-PINT

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • Long noncoding RNAs (lncRNAs) are emerging therapeutic targets for various diseases, including cancers.
  • Approved RNA-based therapies highlight the potential of lncRNA therapeutics.
  • LINC-PINT is a significant lncRNA target due to its functions and association with the tumor suppressor gene TP53.

Purpose of the Study:

  • To explore the therapeutic potential of lncRNAs, focusing on LINC-PINT.
  • To investigate the role of LINC-PINT in cancer progression and its clinical relevance.
  • To assess LINC-PINT as a potential biomarker for immune responses in colon adenocarcinoma.

Main Methods:

  • Literature review and analysis of existing studies on lncRNAs and LINC-PINT.
  • Examination of LINC-PINT's association with TP53 and its tumor suppressor activities.
  • Investigation of LINC-PINT's role in immune responses, particularly in colon adenocarcinoma.

Main Results:

  • LINC-PINT exhibits tumor suppressor activity, similar to p53, impacting cancer progression.
  • LINC-PINT's molecular targets are relevant to current clinical practices.
  • LINC-PINT is associated with immune responses in colon adenocarcinoma, suggesting biomarker potential.

Conclusions:

  • LINC-PINT holds significant promise as a therapeutic target and a diagnostic/prognostic marker for cancer.
  • LINC-PINT's association with immune responses suggests its utility in predicting responses to immune checkpoint inhibitors.
  • Further research into LINC-PINT could lead to novel cancer diagnostics and therapeutics.
Keywords:
Cancer biomarkersCancer therapyColon adenocarcinoma (CAC)Immune checkpoint inhibitorsLINC-PINTLncRNAPINTology

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

1.6K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.9K